Trailing-twelve-month (TTM) revenue is $18.01 Billion with a year-over-year growth of +26.05%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $3,768,236,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-03 |
| Q4 FY2025Period ended 2025-12-31 | $3,719,087,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-27 |
| Q1 FY2026Period ended 2026-03-31 | $3,688,657,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-01 |
| Q2 FY2026Period ended 2026-06-30 | $6,831,191,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-31 |
| TTM revenue | $18,007,171,000 |
Current P/S: $26,022,162,300 market capitalization ÷ $18,007,171,000 TTM revenue = 1.45x.
Market capitalization source: FMP quote. Quote observed 2026-09-11T20:00:02.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $6.83B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-12T00:16:13.692Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2024-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20192019-12-31 · USD | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD |
|---|---|---|---|---|---|---|
| Insurance-Domestic Segment | $6.4B | $6.5B | $7.6B | $8.4B | $10.0B | $11.2B |
| Reinsurance and Monoline Excess Segment | N/A | N/A |
$18.01B
$18.01 Billion
+26.05%
vs. $14.29B a year ago (TTM)
+15.38%
5 Year compound annual growth rate
1 Year
+26.05%
3 Year
+15.69%
5 Year
+15.38%
10 Year
+9.09%
15 Year
+9.05%
20 Year
+6.32%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $14.71B | +$1.07B | +7.82% |
| 2024 | $13.64B | +$1.50B | +12.32% |
| 2023 | $12.14B | +$976.44M | +8.74% |
| 2022 | $11.17B | +$1.71B | +18.10% |
| 2021 | $9.46B | +$1.36B | +16.75% |
| 2020 |
TTM Growth
+26.05%
3-Year CAGR
+15.69%
5-Year CAGR
+15.38%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
| $1.2B |
| $1.5B |
| N/A |
| Reinsurance-Global Segment | $878M | $1.0B | $1.2B | N/A | N/A | $1.7B |
|---|
| $8.10B |
| +$196.73M |
| +2.49% |
| 2019 | $7.90B | +$210.54M | +2.74% |
| 2018 | $7.69B | ($319.28M) | (3.99%) |
| 2017 | $8.01B | +$356.75M | +4.66% |
| 2016 | $7.65B | +$447.73M | +6.21% |
